USANA Health Sciences, Inc. (USNA) Q3 2024 Earnings Call Transcript Summary
USANA Health Sciences, Inc. (USNA) Q3 2024 Earnings Call Transcript Summary
Increased active customer counts by 7% year-over-year in China.The following is a summary of the USANA Health Sciences, Inc. (USNA) Q3 2024 Earnings Call Transcript:
以下是USANA健康科學公司（USNA）2024年第三季度業績會議呼叫成績單摘要：
Financial Performance:
金融業績：
Third quarter net sales fell short of expectations, with a decline in the China market contributing to lower than expected performance.
Anticipates a challenging operating environment through the remainder of the year.
第三季度淨銷售額未達預期，中國市場下滑導致表現低於預期。
預計在年底前面臨挑戰性的經營環境。
Business Progress:
業務進展：
Increased active customer counts by 7% year-over-year in China.
Hosted a successful American-Europe Convention in Las Vegas, leading to positive feedback and engagement from associate sales leaders.
Launched new products including Celavive Resurfacing Serum and Whey Protein Isolate in the US and Canada with plans to expand to other markets.
Developing additional products set to be introduced throughout the next year.
中國活躍客戶數量同比增長7%。
在拉斯維加斯舉辦了一次成功的美國-歐洲大會，獲得正面反饋並與銷售領導人員進行了互動。
推出了包括Celavive Resurfacing Serum和Whey Protein Isolate在美國和加拿大市場的新產品，並計劃拓展到其他市場。
計劃在接下來的一年內推出更多產品。
Opportunities:
機會：
Planning to increase promotional activity in the fourth quarter to support business momentum.
Innovation and quick market adaptation of new products due to improved product development processes.
計劃在第四季度增加促銷活動，以支持業務勢頭。
由於改進的產品開發流程，創新和快速適應新產品的市場。
Risks:
風險：
Continued challenging operating environment anticipated, especially impacting key markets like China where consumer spending might not recover swiftly.
預計持續具有挑戰性的運營環境，特別是對中國等關鍵市場的影響，消費支出可能不能迅速恢復。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
